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Effect of the VWF promoter (GT)n repeat and SNP c.-2527G>A on
circulating VWF levels under normal conditions
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Circulating von Willebrand factor (VWF) protein levels in plasma (VWF:Ag) of healthy
individuals can be affected by a number of factors, either physiological and environmental
such as stress, or genetic such as ABO blood group [1]. It has previously been suggested that
VWF:Ag levels could be partly determined by four single nucleotide polymorphisms (SNP)
in the promoter region of VWF; c.-3268C>G, c.-2709T>C, c.-2661G>A and c.-2527G>A,
segregating predominantly as two haplotypes, GCAG (haplotype 1) or CTGA (haplotype 2),
with the latter being associated with lower VWF:Ag levels [2,3]. Shear stress has been
shown to enhance VWF promoter activity, with a dinucleotide (GT)n short tandem repeat
(STR) located at c.-2144_-2105 in the VWF promoter exhibiting size-dependent mediation
of this stress-induced transactivation [4]. Studies on Cushing’s syndrome patients suggest
that both the SNPs and STR influence a glucocorticoid-induced increase in plasma VWF:Ag
level [5,6]. However, other studies have failed to reproduce this SNP and STR association
[7,8]. The current study reports the largest investigation of the association between SNP
c.-2527G>A, the (GT)n STR, and VWF:Ag levels in healthy controls (HC) from the
MCMDM-1VWD study [9] under normal conditions, while controlling for the effect of
ABO blood group.
ABO blood group, age and VWF:Ag levels were available for 1115 European male and
female healthy controls (HC) from nine countries [9]. None had been referred to a specialist
centre due to bleeding problems. VWF:Ag levels were determined at a single centre [9].
Genotypes for the c.-2527G>A SNP were determined using TaqMan allelic discrimination
(ABI 7900; Applied Biosystems, Europe BV, Warrington, UK). The VWF region containing
the (GT)n STR was amplified by PCR (primer sequences available on request), sequenced
and analysed on an ABI PRISM™ 3730 DNA analyser (Applied Biosystems). Analysis of
two homozygous samples showed that (GT)n alleles 181bp and 185bp long corresponded to
(GT)19 and (GT)21 respectively. Hardy-Weinberg equilibrium, allele frequencies and
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linkage disequilibrium analyses were performed using SNPStats:
http://bioinfo.iconcologia.net/index.php?module=Snpstats (accessed August 2010).
Associations between genotypes and VWF:Ag levels were assessed using Kruskal Wallis
tests (GraphPad Prism v5.00, GraphPad Software Inc, San Diego, CA, USA). p values <0.05
were considered to be statistically significant in all tests.
Genotype data for the c.-2527G>A SNP were used for investigation of a genotype-VWF:Ag
relationship. There was no significant association between VWF:Ag level and SNP
genotype before or after controlling for the effect of ABO blood group (Table 1A), thus
contradicting previous results of a smaller study on blood group O Canadian HC (n=250) [3]
which identified a significant association (p=0.006). Presence of an extended founder
haplotype in the Canadian population with an effect on VWF level could be a possible
explanation. 100 European HC from two countries were also genotyped for the four
promoter SNP examined in the Canadian study and the SNP were shown to be in complete
linkage disequilibrium (D’=0.999, p<0.0001), segregating as the two previously reported
haplotypes GCAG (haplotype 1) and CTGA (haplotype 2). No association of genotype with
VWF:Ag levels was found in this subgroup (data not shown).
Genotyping of the STR identified alleles ranging in size from (GT)16 to (GT)27 with a
bimodal distribution, i.e. a peak at (GT)19 (37.2%) and another at (GT)21 (32.2%). The
genotype (GT)19/(GT)21 was the most frequent (23.8%), followed by (GT)19/(GT)19
(13.3%) and (GT)21/(GT)21 (10.2%). GT repeat alleles were divided into two subclasses for
ease of analysis [8]. Small (S) alleles included all those <(GT)20 and large (L) included
those ᚣ(GT)20. Based on this approach, 42.8% of alleles were (GT)S and 57.2% were (GT)L;
18% HC had genotype S/S, 50% had S/L and 32% had L/L, while genotype distribution was
consistent with Hardy-Weinberg equilibrium (p=0.42).
In contrast to the results of a smaller study (n=394 HC) reporting a lack of association
between (GT)n genotypes and VWF:Ag levels in HC [8], in this study VWF:Ag values were
lower in HC homozygous for S alleles compared to HC heterozygous or homozygous for L
alleles (S/S vs S/L vs L/L = 92.0 vs 97.0 vs 100.0 IU/dL, p=0.027) (Table 1B). This
association was not maintained when HC of only blood group O were examined (S/S vs S/L
vs L/L = 80.0 vs 80.0 vs 82.0 IU/dL, p=0.524), but was observed when examining HC of
non-O blood groups (S/S vs S/L vs L/L = 101.0 vs 107.5 vs 114.0 IU/dL, p=0.020) (Table
1B). These data suggest an effect of GT repeat length on VWF levels of ~10% and are in
agreement with recent findings suggesting that longer GT repeats induce a larger increase in
VWF promoter activity than shorter ones under shear stress conditions [4]. A statistically
significant association amongst O blood group HC may only be observed with analysis of a
larger number of individuals in this subcategory.
A small degree of linkage was observed between the c.-2527G>A SNP and the (GT)n repeat
(D’=0.661, R2=0.597, p<0.0001). The two most frequent haplotypes (S/G and L/A)
accounted for ~80% of HC (49.9% and 30.5% respectively). The most frequent genotypes
resulting from homozygosity or heterozygosity for the above haplotypes were S/L-G/A
(32.8%), L/L-A/A (23.6%) and S/S-G/G (10.1%). Other allele combinations comprised the
remaining 33.5% of genotypes. The association between the three genotypes (S/L-G/A, L/L-
A/A, S/S-G/G) and VWF:Ag levels was examined in order to identify a potential
cooperative effect of the STR and SNP loci on VWF:Ag levels. The results shown in Table
1C suggest that these two polymorphic regions have no significant cooperative effect on
VWF:Ag levels in the EU population, before or after controlling for the effect of ABO blood
group on VWF:Ag levels (Table 1C). This suggests that an effect on VWF:Ag levels is
mediated only by the (GT)n repeat.
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In conclusion, this study has provided evidence that the c.-2527G>A VWF promoter SNP
does not have a significant effect on levels of VWF in the EU population. In contrast, the
VWF (GT)n STR exhibited a small effect on VWF levels, mediated by its length. A SNP/
STR cooperative effect on the regulation of VWF:Ag levels in HC was excluded. This is the
largest study examining the potential influence of these loci on VWF levels in HC while
controlling for the effect of ABO blood group and is the first study to show a significant
effect of the c.-2144_-2105 locus on VWF levels under normal conditions.
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Table 1
Association of genotype at VWF locations (A) c.-2527, B) (GT)n and C) (GT)n plus c.-2527 with median levels of VWF in healthy controls from the
MCMDM-1VWD study controlling for blood group.
Analysis Genotype and ABO blood group Mean age (SD) n* Median VWF:Ag level (IU/dL) (Range†) p value
A) c.-2527G>A
All‡ 1115
G/G 40.7 (12.5) 162 96.5 (74.8–119.5)
0.961G/A 40.2 (11.9) 521 98.0 (77.0–120.0)
A/A 40.5 (11.4) 432 96.0 (75.0–122.0)
O 410
G/G 41.6 (11.3) 51 84.0 (66.0–106.0)
0.747G/A 42.1 (12.5) 191 80.0 (64.0–98.0)
A/A 41.2 (10.6) 168 78.5 (66.0–99.0)
Non-O 678
G/G 40.8 (13.1) 104 106.0 (81.0–133.0)
0.852G/A 39.3 (11.4) 319 107.0 (89.0–126.0)
A/A 40.2 (12.0) 255 112.0 (86.0–129.0)
B) (GT)n
All 1105
S/S 41.0 (11.5) 196 92.0 (70.3–114.5)
0.027S/L 40.3 (11.8) 555 97.0 (76.0–120.0)
L/L 40.6 (12.3) 354 100.0 (78.0–125.0)
O 408
S/S 41.8 (11.0) 71 80.0 (62.0–99.0)
0.524S/L 42.0 (11.7) 199 80.0 (65.0–102.0)
L/L 40.9 (11.6) 138 82.0 (67.8–101.3)
Non-O 569
S/S 41.1 (11.7) 118 101.0 (77.8–124.3)
0.020S/L 39.3 (11.8) 344 107.5 (86.0–127.0)
L/L 40.7 (12.8) 207 114.0 (91.0–132.0)
C) c.-2527G>A & (GT)n
All 727
S/S-G/G 41.3 (12.0) 110 92.0 (71.8–116.3) 0.314
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Analysis Genotype and ABO blood group Mean age (SD) n* Median VWF:Ag level (IU/dL) (Range†) p value
S/L-G/A 39.7 (11.7) 358 96.5 (77.8–120.0)
L/L-A/A 40.7 (11.9) 259 98.0 (76.0–125.0)
O 278
S/S-G/G 41.5 (10.6) 39 84.0 (66.0–101.0)
0.714S/L-G/A 41.8 (12.0) 134 81.5 (65.8–104.0)
L/L-A/A 40.8 (10.7) 105 85.0 (67.0–103.0)
Non-O 432
S/S-G/G 42.1 (12.5) 65 102.0 (76.5–134.5)
0.387S/L-G/A 38.6 (11.4) 219 107.0 (87.0–126.0)
L/L-A/A 40.8 (12.9) 148 112.5 (88.0–130.0)
*ABO blood group data were available for 1088 out of 1115 HC.
†
Range = 25th–75th percentile.
‡All: all blood groups; O: blood group O only; Non-O: blood groups other than O.
SD: Standard deviation
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